Astrazeneca PLC (AZN) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($0.66 million) and the uptick to downtick ratio was 0.31. The transaction value on upticks was $0.3 million and on downticks, the transaction value was $0.96 million. The transaction value of block trades during downticks was $0.89 million. The money flow was negative ($0.89 million), indicating the traders were booking profit on the price strength. Astrazeneca PLC (AZN) rose $0.23 at $30.53, during intraday Wednesday , a rise of 0.76% over the previous days close.
Also, Argus Research initiates coverage on Astrazeneca PLC (NYSE:AZN) The shares have been rated Hold. The rating by the firm was issued on July 12, 2016.
Astrazeneca PLC (NYSE:AZN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $30.49 and $30.47 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $30.73. The buying momentum continued till the end and the stock did not give up its gains. It closed at $30.57, notching a gain of 0.89% for the day. The total traded volume was 5,953,045 . The stock had closed at $30.30 on the previous day.
The stock has recorded a 20-day Moving Average of 2.89% and the 50-Day Moving Average is 4.72%.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).